Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
about
Pharmacological treatment options for mast cell activation diseaseClinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer.Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis.
P2860
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Thalidomide in systemic mastoc ...... , multicentre, phase II study.
@ast
Thalidomide in systemic mastoc ...... , multicentre, phase II study.
@en
type
label
Thalidomide in systemic mastoc ...... , multicentre, phase II study.
@ast
Thalidomide in systemic mastoc ...... , multicentre, phase II study.
@en
prefLabel
Thalidomide in systemic mastoc ...... , multicentre, phase II study.
@ast
Thalidomide in systemic mastoc ...... , multicentre, phase II study.
@en
P2093
P2860
P50
P356
P1476
Thalidomide in systemic mastoc ...... , multicentre, phase II study.
@en
P2093
Bernard Grosbois
Bérengère Gruson
Claire Larroche
Cristina Livideanu
Danielle Canioni
Fanny Lanternier
Gandhi Damaj
Guillaume Chaby
Henri Sevestre
Isabelle Durieu
P2860
P304
P356
10.1111/BJH.12265
P407
P577
2013-02-22T00:00:00Z